Publication:
Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8

Simple item page
dc.conference.dateMAY 03-05, 2022
dc.conference.titleEuropean-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress
dc.contributor.authorJerusalem, G.
dc.contributor.authorPrat, A.
dc.contributor.authorSalgado, R. F.
dc.contributor.authorReinisch, M.
dc.contributor.authorSaura, C.
dc.contributor.authorRuiz Borrego, M.
dc.contributor.authorNikolinakos, P.
dc.contributor.authorFilian, J.
dc.contributor.authorAdes, F.
dc.contributor.authorHuang, N.
dc.contributor.authorMazzei-Abba, A.
dc.contributor.authorTolaney, S. M.
dc.contributor.authoraffiliation[Jerusalem, G.] Ctr Hosp Univ Sart Tilman, Dept Med Oncol, Liege, Belgium
dc.contributor.authoraffiliation[Prat, A.] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Salgado, R. F.] GZA Ziekenhuizen Campus SintAugustinus, Dept Pathol, Antwerp, Belgium
dc.contributor.authoraffiliation[Reinisch, M.] Kliniken Essen Mitte, Interdisciplinary Breast Unit, Essen, Germany
dc.contributor.authoraffiliation[Saura, C.] Vall dHebron Inst Oncol VHIO, Breast Canc Unit, Barcelona, Spain
dc.contributor.authoraffiliation[Ruiz Borrego, M.] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Nikolinakos, P.] Univ Canc & Blood Ctr, Clin Res, Athens, GA USA
dc.contributor.authoraffiliation[Filian, J.] Bristol Myers Squibb, Clin Res, Princeton, NJ USA
dc.contributor.authoraffiliation[Ades, F.] Bristol Myers Squibb, Clin Res, Lawrenceville, NJ USA
dc.contributor.authoraffiliation[Huang, N.] Bristol Myers Squibb, Safety, Princeton, NJ USA
dc.contributor.authoraffiliation[Mazzei-Abba, A.] Bristol Myers Squibb, Biostat, Bristol, Switzerland
dc.contributor.authoraffiliation[Tolaney, S. M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
dc.date.accessioned2023-05-03T14:40:01Z
dc.date.available2023-05-03T14:40:01Z
dc.date.issued2022-05-05
dc.identifier.doi10.1016/j.annonc.2022.03.108
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422004872/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21901
dc.identifier.wosID792494100094
dc.issue.number3
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen del Rocío
dc.page.numberS165-S166
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleNeoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía